Search Results - "Burstein HJ"

Refine Results
  1. 1

    Radiation therapy for ductal carcinoma in situ: a decision analysis.

    Authors: Punglia RS Burstein HJ Weeks JC et al.

    Source: Cancer (0008543X). Feb2012, Vol. 118 Issue 3, p603-611. 9p.

    PDF Full Text
    Save to List
  2. 2

    American Society of Clinical Oncology clinical practice guideline update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer.

    Authors: Burstein HJ Griggs JJ Prestrud AA et al.

    Source: Journal of Oncology Practice. Sep2010, Vol. 6 Issue 5, p243-246. 4p.

    Save to List
  3. 3

    Case records of the Massachusetts General Hospital. Case 25-2009. A 36-year-old woman with hormone-receptor-positive breast cancer.

    Authors: Burstein HJ Souter I D'Alessandro HA et al.

    Source: New England Journal of Medicine. 8/13/2009, Vol. 361 Issue 7, p699-707. 9p.

    Save to List
  4. 4

    Ductal carcinoma in situ of the breast.

    Authors: Burstein HJ Polyak K Wong JS et al.

    Source: New England Journal of Medicine. 4/1/2004, Vol. 350 Issue 14, p1430-1441. 12p.

    Save to List
  5. 5

    Primary care. Primary care for survivors of breast cancer.

    Authors: Burstein HJ Winer EP

    Source: New England Journal of Medicine. 10/12/2000, Vol. 343 Issue 15, p1086-1094. 9p.

    Save to List
  6. 6

    Use of alternative medicine by women with early-stage breast cancer.

    Authors: Burstein HJ Gelber S Guadagnoli E et al.

    Source: New England Journal of Medicine. 06/03/99, Vol. 340 Issue 22, p1733-1739. 7p.

    Save to List
  7. 7

    The distinctive nature of HER2-positive breast cancers.

    Authors: Burstein HJ (AUTHOR)

    Source: New England Journal of Medicine. 10/20/2005, Vol. 353 Issue 16, p1652-1654. 3p.

    Save to List
  8. 8

    Beyond tamoxifen -- extending endocrine treatment for early-stage breast cancer.

    Authors: Burstein HJ (AUTHOR)

    Source: New England Journal of Medicine. 11/6/2003, Vol. 349 Issue 19, p1857-1859. 3p.

    Save to List
  9. 9

    PET-CT scans for finding breast cancer.

    Authors: Burstein HJ (AUTHOR)

    Source: Harvard Health Letter. May2009, Vol. 34 Issue 7, p2-2. 1p.

    URL: 37697337

    PDF Full Text
    Save to List
  10. 10

    Molecular origins of cancer.

    Authors: Burstein HJ Schwartz RS

    Source: New England Journal of Medicine. 1/31/2008, Vol. 358 Issue 5, p527-527. 1p.

    URL: 28751937

    Save to List
  11. 11

    Patient advocates' role in clinical trials: Perspectives from Cancer and Leukemia Group B investigators and advocates.

    Authors: Katz ML Archer LE Peppercorn JM et al.

    Source: Cancer (0008543X). Oct2012, Vol. 118 Issue 19, p4801-4805. 5p.

    PDF Full Text
    Save to List
  12. 12

    Ductal carcinoma in situ of the breast.

    Authors: Brown AP Ellison MC Kenney PJ et al.

    Source: New England Journal of Medicine. 7/22/2004, Vol. 351 Issue 4, p399-402. 4p.

    Save to List
  13. 13

    Letrozole in breast cancer.

    Authors: Buzdar AU Hietanen P Mäkelä M et al.

    Source: New England Journal of Medicine. 2/12/2004, Vol. 350 Issue 7, p727-730. 4p.

    Save to List
  14. 14

    Progression-Free Survival in Metastatic Breast Cancer by Local Investigators vs Blinded Independent Central Review: A Systematic Review and Meta-Analysis.

    Authors: Ravani LV Bagheri Z Kalinsky K et al.

    Source: JAMA oncology [JAMA Oncol] 2026 Jul 16. Date of Electronic Publication: 2026 Jul 16.

    Publication Type: Journal Article

    Journal Info: Publisher: American Medical Association Country of Publication: United States NLM ID: 101652861 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2374-2445 (Electronic) Linking ISSN: 23742437 NLM ISO Abbreviation: JAMA Oncol Subsets: MEDLINE

    Save to List
  15. 15

    Now or later? Switching therapies in metastatic breast cancer.

    Authors: Valenza C Regan MM Burstein HJ

    Source: The Lancet. Oncology [Lancet Oncol] 2026 Jul 13. Date of Electronic Publication: 2026 Jul 13.

    Publication Type: Journal Article

    Journal Info: Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 100957246 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-5488 (Electronic) Linking ISSN: 14702045 NLM ISO Abbreviation: Lancet Oncol Subsets: MEDLINE

    Save to List
  16. 16

    Breast Cancer, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology.

    Authors: Gradishar WJ Moran MS Abraham J et al.

    Source: Journal of the National Comprehensive Cancer Network : JNCCN [J Natl Compr Canc Netw] 2026 Jul; Vol. 24 (7).

    Publication Type: Journal Article; Practice Guideline

    Journal Info: Publisher: Harborside Press Country of Publication: United States NLM ID: 101162515 Publication Model: Print Cited Medium: Internet ISSN: 1540-1413 (Electronic) Linking ISSN: 15401405 NLM ISO Abbreviation: J Natl Compr Canc Netw Subsets: MEDLINE

    Save to List
  17. 17

    SACI-IO HR+: A randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer.

    Authors: Garrido-Castro AC Kim SE Li T et al.

    Source: Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2026 Jun 20. Date of Electronic Publication: 2026 Jun 20.

    Publication Type: Journal Article

    Journal Info: Publisher: Elsevier Country of Publication: England NLM ID: 9007735 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1569-8041 (Electronic) Linking ISSN: 09237534 NLM ISO Abbreviation: Ann Oncol Subsets: MEDLINE

    Save to List
  18. 18

    Final outcomes of the SOFT and TEXT phase III trials in premenopausal hormone receptor-positive early breast cancer.

    Authors: Francis PA Pagani O Fleming GF et al.

    Corporate Authors: Francis PA Pagani O Fleming GF et al.

    Source: Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2026 Jun 01. Date of Electronic Publication: 2026 Jun 01.

    Publication Type: Journal Article

    Journal Info: Publisher: Elsevier Country of Publication: England NLM ID: 9007735 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1569-8041 (Electronic) Linking ISSN: 09237534 NLM ISO Abbreviation: Ann Oncol Subsets: MEDLINE

    Save to List
  19. 19

    Impact of adding palbociclib on treatment adherence to ongoing adjuvant endocrine treatment in the global randomized PALLAS randomized trial in patients with early breast cancer.

    Authors: Shinn E Zahrieh D DeMichele A et al.

    Source: Breast cancer research and treatment [Breast Cancer Res Treat] 2025 Jun; Vol. 211 (2), pp. 385-397. Date of Electronic Publication: 2025 Mar 27.

    Publication Type: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study

    Journal Info: Publisher: Kluwer Academic Country of Publication: Netherlands NLM ID: 8111104 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-7217 (Electronic) Linking ISSN: 01676806 NLM ISO Abbreviation: Breast Cancer Res Treat Subsets: MEDLINE

    HTML Full Text PDF Full Text
    Save to List
  20. 20

    Corrigendum to 'Long-term outcomes with adjuvant CDK4/6 inhibitors: who benefits most?': [Annals of Oncology. Volume 37, Issue 2, February 2026, Pages 133-135].

    Authors: O'Meara TA Burstein HJ

    Source: Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2026 Apr 07. Date of Electronic Publication: 2026 Apr 07.

    Publication Type: Published Erratum

    Journal Info: Publisher: Elsevier Country of Publication: England NLM ID: 9007735 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1569-8041 (Electronic) Linking ISSN: 09237534 NLM ISO Abbreviation: Ann Oncol Subsets: MEDLINE

    Save to List

Search Tools: